Table 1.

Correlation of IL15 expression in the serum with patient clinical outcomes

State of diseaseIL15 (pg/mL)Response to therapyClinical outcome (at 1 year)
Smoldering116.9NELost FU
Relapse3.6NEDeath
MGUS4.9NEOnset
Relapse1.12NEDeath
Smoldering1.86NEOnset
Relapse12.4PR+Relapse
Relapse44.2NEDeath
Onset14.2VGPR+Relapse
Relapse446.2PD+++Relapse
Relapse12.4PR+Relapse
Onset8.9NEDeath
  • NOTE: Serum IL15 levels were compared with clinical outcomes at 1 year in patients with multiple myeloma. IL15 was measured by enzyme-linked immunosorbent assay (ELISA).

  • Abbreviations: NE, not evaluable; Lost FU, lost follow-up; PR, partial response; VGPR, very good partial response; PD, progressive disease. +, 1 relapse; +++, > 1 relapse.